ALFA Finder
17:25 IST
NSE
Earnings Call
Accretion Pharmaceuticals Investor Presentation: Key Takeaways
H1 FY27 revenue ₹55.04 Cr (+25.83% YoY), PAT ₹8.20 Cr (+72.63%), EBITDA margin 22.48%. Export share rose to 18.15%.
Accretion Pharmaceuticals Ltd
- Share price
- ₹203.75
- Market cap
- ₹226.5 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 23.4×Sector 43.8×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
17:24 IST
NSE
Results Update
Accretion Pharmaceuticals Results Update
Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.
12:54 IST
NSE
Financial Results
Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY
Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.
- Key figure
- Net profit ₹8.2 Cr · +70.8% YoY